drugset
Drugs / AdCh63 ME-TRAP
last change Jul 2013 re-read 2 minutes ago

AdCh63 ME-TRAP

also known as ChAd63 ME-TRAP

Vaccine

Developed for
malaria
Investigated by
University of Oxford · European and Developing Countries Clinical Trials Partnership (EDCTP) · Kenya Medical Research Institute

Trials 7 · a red edge is where a trial was stopped

today NCT01450293 · Ph 1 NCT01364883 · Ph 1 NCT01142765 · Ph 1/2 NCT01373879 · Ph 1 NCT01379430 · Ph 1 NCT00890760 · Ph 1/2 NCT00890019 · Ph 1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT01450293 Oct 2011 → Mar 2013 malaria University of Oxford Completed No outcome recorded
Phase 1 NCT01364883 Jul 2011 → Jul 2013 malaria University of Oxford Completed No outcome recorded
Phase 1 NCT01373879 Jun 2010 → Dec 2011 malaria University of Oxford Completed No outcome recorded
Phase 1 NCT01379430 Jun 2010 → May 2011 malaria University of Oxford Completed No outcome recorded
Phase 1 NCT00890019 Jul 2007 → Aug 2011 malaria University of Oxford Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT01142765 Jun 2010 → Mar 2011 malaria University of Oxford Completed No outcome recorded
Phase 1/2 NCT00890760 Mar 2009 → Feb 2010 malaria University of Oxford Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as AdCH63 ME-TRAP “The purpose of this trial is to assess the safety and immunogenicity of MVA ME-TRAP and AdCH63 ME-TRAP candidate vaccines in healthy children and adult volunteers in a malaria...” NCT01373879 ↗
7

“They will be primed with AdCh63 ME-TRAP administered intramuscularly and boosted several times with AdCh63 ME-TRAP and MVA ME-TRAP according to various schedules.” NCT01364883 ↗

NCT00890019 ↗

NCT01450293 ↗

NCT00890760 ↗

NCT01379430 ↗

NCT01142765 ↗

NCT01373879 ↗
Known as ChAd63 ME-TRAP “Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and...” PMID 23526949 ↗ Mar 2013
Modality Vaccine “a novel malaria vaccine, AdCh63 ME-TRAP, simian adenovirus encoding Plasmodium falciparum antigens” NCT00890019 ↗
Route Intramuscular “AdCh63 ME-TRAP administered intradermally or intramuscularly” NCT00890019 ↗